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INTRODUCTION 
Diabetes mellitus (DM), is a heterogeneous group 
of metabolic disorders in which there is elevation in 
blood glucose level over a prolonged time 
period.
1
Diabetes is found in about 300 million people 
world-wide, and the number keep on increasing. It 
occurs as the body is unable to produce enough insulin 
as much required, either because of impaired insulin 
secretion, impaired insulin action, or both.
1
Lack of 
proper treatment of diabetes may lead to 
manycomplications.
2
Acute complications because of 
untreated diabetes include diabetic 
ketoacidosis and nonketotic hyperosmolar 
coma
3
. Serious chronic complications of untreated 
diabetes include cardiovascular disease, stroke, chronic 
kidney failure, foot ulcers,  retina damage.
 
Diabetes occurs due to either the pancreas not 
producing enough insulin as much required by the 
body or the cells of the body not responding properly to 
the insulin produced i.e. cells desensitized of insulin 
produced. There are three main types of diabetes 
mellitus: 
 Type 1 DM occurs due to the failure of beta cells of 
the islets of Langerhans in the pancreas to produce 
enough insulin as per requirement, leading to 
insulin deficiency.  It is also known as "insulin-
dependent diabetes mellitus" (IDDM). The cause of 
Type 1 DM is exactly not known.
2
It can be further 
differentiated as immune-mediated or idiopathic. 
Majority of cases of type 1 diabetes is of the 
immune-mediated nature, that occurs due to T-cell-
mediated autoimmune attack leads to the loss of 
beta cells and thereforeinsulin.
3
 
 Type 2 DM initiates with insulin resistance or 
insulin desensitization, a condition in which cells 
fail to respond to insulin properly.
2
 Chronic 
persisting of such condition causes a lack of insulin 
may also develop.
4
It is also known as "non insulin-
dependent diabetes mellitus" (NIDDM) or "adult-
onset diabetes". The major cause is excessive body 
weight and lack of exercise.
2
 Generally oral 
hypoglycemic drugs are administered for such 
cases for example: sulphonylurea’s, biguanides etc. 
 Gestational diabetes, is the third main form of DM 
and occurs during pregnancy, when pregnant 
women without a previous history of diabetes 
develop a high blood glucose level. It occurs in 
about 2–10% of all pregnancies and may improve 
or disappear after delivery.
6
 
ABSTRACT 
Objectives: A review article on novel approaches on oral insulin delivery. 
Data Sources:  Review articles on oral insulin delivery, Books.  
Study selection: This review consist of importance as well as current approaches for oral insulin delivery like liposomes, 
nanospheres, nanocubeics, erythrocytes, thiolated chitosan tablets, chitosan microspheres etc. 
Summary of content article: Type 1 diabetes mellitus is a metabolic disorder which arouse as a major health problem 
worldwide. Clinical management of insulin is done by insulin replacement therapy and current route of its administration is 
through subcutaneous injection having many challenges. To overcome the problems associated with insulin injections novel 
approaches for insulin administration are being explored. If insulin is administered orally, in the stomach rapid enzymatic 
degradation of insulin occurs and in the intestine insulin is digested and hence inactivated by the action of proteolytic enzymes 
occurs. This review consist of importance as well as current approaches for oral insulin delivery like liposomes, nanospheres , 
nanocubeics, erythrocytes, thiolated chitosan tablets, chitosan microspheresetc. This review also gives the information about 
current market status of oral insulin5. 
Conclusion: The oral route is considered to be most acceptable and convenient route of administration for chronic therapy. 
Attempts have been made to achieve oral insulin delivery using various systems. Liposomes, microemulsions, nanocubicles, 
thiolated chitosan, chitosan microspheres and so forth have been prepared for the oral delivery of insulin. 
Keywords: oral insulin, approaches for oral insulin delivery , current market status. 
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The current route of insulin administration is via 
subcutaneous route through which insulin is delivered 
to the body in non-physiological manner having many 
challenges. Hence novel approaches for insulin delivery 
are being explored and investigated. Challenges which 
precipitate via oral route of administration of insulin 
are: rapid enzymatic degradation in the stomach, 
inactivation and digesion by proteolytic enzymes in 
intestinal lumen and poor permeability across intestinal 
epithelium because of high molecular weight and lack 
of lipophilicity.  Nanosphere, thiolated chitosan tablets, 
chitisan-microsphers, microemulsions, liposomes, 
nanocubicles and so forth have been prepared for the 
oral delivery of insulin.
5
 
PROBLEMS ASSOCIATED WITH PRESENT 
ROUTES FOR INSULIN ADMINISRATION
 
The present route of insulin administration is by 
subcutaneous route by which insulin is presented to the 
body of patient in a non – physiological manner.5This 
route of administration of insulin has many challenges. 
For a diabetes mellitus patient insulin replacement 
therapy is performed injecting insulin  subcutaneously 
frequenty, is having many inherent disadvantages which 
include local pain, inconvenience due to repetative 
injection, and  hypoglycemia may occurs as a result of 
over dose, itching, allergy, hyperinsulanemia, and 
insulin lipodistrophy around the site of injection. 
Further, clinical trials have shown that even on 
injectables insulin treatment , a significant percentage 
of patients fails to attain lasting glycemic control due to 
non-complience.
5,15
As of these problems , novel 
approaches for insulin delivery are being explored , 
including oral and transdermal ,nasal, rectal, 
pulmonary, uterine and ocular delivery as well as  s.c. 
implants . Delivery options that use dermal, nasal, and 
oral have been explored.
5,16,17 
 
 
Figure 1: Possible routes insulin administration
9 
 
IMPORTANCE OF ORAL DELIVERY OF 
INSULIN 
The oral route of drug delivery is considered to be most 
convenient route with good patient compliance for 
administration in case of chronic therapy.  
Administration of insulin orally will help to eliminate 
the pain caused by injection , psychological barriers 
associated with multiple daily injections such as needle 
anxiety
7
 and possible infections.
8
Further, oral insulin  is 
advantageous because it is delivered directly on the 
liver, its primary site of action , via the portal 
circulation , a mechanism very similar to endogenous 
insulin, subcutaneous insulin treatment subcutaneous 
insulin treatment however does not replicate the normal 
dynamics of endogenous insulin release , resulting in 
failure to achieve release a lasting glycemic control in 
patients.
5,11,12,13
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Figure 2: Development of effective oral insulin delivery
9
 
 
CHALLENGES TO OVERCOME FOR ORAL 
INSULIN DELIVERY 
Because of inactivation  and digestion by proteolytic 
enzymes in the intestinal lumen, rapid enzymatic 
degradation in the stomach , and poor permeability 
across intestinal epithelium because of its high 
molecular weight and lack of lipophilicity, peptides and 
proteins such as insulin cannot be administered via the 
oral route.
18,19,20
 The oral bioavailability of most of the 
peptides and proteins therefore is less than 1%.
5
The 
challenge here is to improve the  oral bioavailability to 
at least between 30-50%.
21
 
 ENZYMATIC BARRIERS IN 
GASTROINTESTINAL TRACT 
The digestive process occurring in  the gastrointetinal 
tract leads to breakdown of all type of  proteins and 
peptides.
22
Insulin therefore undergoes enzymatic 
degradation by pepsin and pancreatic proteolytic 
enzyme such as trypsin and alpha-chymotrypsin.
5,14,23
 
Insulin degraded by cytosolic enzyme insulin degrading 
enzyme (IDE).
24
 Overall , insulin is subjected to acid 
catalysed degradation in the stomach , luminal 
degradation  in the intestinal and intracellular 
degradation.
5
  Brush border enzymes however does not 
cause proteolytic breakdown of insulin.
14
Hence 
enzymetic barriers has to be overcome for insulin oral 
delivery. 
 INSULIN LOW  PERMEABILITY TO 
INTESTINAL MUCOSA 
 Insulin has low permeability through the intestinal 
mucosa because insulin is   hydrophilic macromolecule 
hence cannot diffuse across epithelial cells through 
lipid-bilayer cell membranes of intestinal mucosa to the 
blood stream.
8,25
There is no evidence of active transport 
for insulin.
5,26
 It has been found however that insulin 
delivery to the mid-jejunum protects insulin from 
gastric and pancreatic enzymes and release from the 
dosage form is enhanced by intestinal micro flora.
5,26,27
 
Hence targeting insulin dosage form to mid jejunum 
may be effective with increased bioavailability. 
 STRENGTH OF DOSAGE FORM:  
The three-dimensional molecular structure plays 
important role in the activity of proteins. Proteins might 
tend to physical and chemical degradation at the time of 
forming dosage form. Proteins’ physical degradation 
involves modification of the native structure to a higher 
order structure while chemical degradation involving 
bond cleavage that results in the formation of a new 
stuctures.
5,14
At the time of dosage formulation 
processing proteins must be characterized for change in 
conformation, size, shape, surface properties, and 
bioactivity.
5
Usinglight scattering, spectrophotometric 
techniques, gel filtration, x-ray diffraction, differential 
scanning calorimeter, and electrophoresis changes in 
conformation, size, shape of protein can be observed. 
APPROACHES FOR ORAL ADMINISTRATION 
OF INSULIN
5
 
Already Attempted Oral Delivery Systemsof 
Insulin:
5 
Generally bioavailability of most of the peptides is very 
negligible or not possible after oral administration in 
gastrointestinal tract
28
 Hence developing successful oral 
insulin delivery system need to overcome the enzymatic 
and physical barriers
22
and effectively conversing the 
bioactivity during formulation processing.
14
 In 
developing oral protein delivery systems with high 
bioavailability, three practical approaches might be 
most helpful:
5, 11
 
1. Effectively modifying physiochemical properties 
such as lipophilicity and enzyme susceptibility. 
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2. Addition of novel function to macromolecules 
(proteins and peptides). 
3. Using improved carrier systems. 
Following approaches can be categorized as various 
oral delivery systems which have been attempted for 
oral delivery of insulin either singly or in a synergistic 
manner: 
Insulin penetration enhancers through intestinal 
mucosa
5
: 
 Insulinis a hydrophilic molecule adsorbed to the apical 
membrane and is internalized by endocytosis.
5,14
Tight 
junctions present between each of the cells in the 
epithelium prevent transport across the cell of water and 
aqueous soluble compounds. Hence, approaches are 
made for modulating tight-junction permeability to 
increase paracellular transport have been studies.
5
 A 
number of absortion enhancers are available that cause 
these tight junctions to open transiently allowing water-
soluble proteins to pass. Use of safe excipients in the 
formulation may enhance absorption.
5,29
Excipients like 
bile salts, surfactants, trisodium citrates, chelating 
agents like EDTA
30
 , labrasol
31
 may be considered to be 
safe but drawbacks with it are lack of specificity for 
insulin, i.e., they allow other undesired  content of the 
intestinal tracts including toxins and pathogens through 
it to the systematic bloodstream
32
, and risk of damage to 
mucous membranes by surfactants and damage of cell 
membrane by chelators
33
 . some further work on 
penetration enhancers have proven  mucoadhesive 
polymers to be safe and efficient intestinal permeation 
enhancers for the absorption of proteineceous drugs.
5, 34, 
35
 
Enzyme Inhibitors:
5
 
Enzyme inhibitors can be used to avoid the rapid 
enzymatic degradation of insulin by enzyme pepsin in 
stomach and other pancreatic proteolytic enzymes in 
gastro intestinal tract. Enzymes inhibitors slowdown the 
rate of degradation of insulin in gastrointestinal tract 
which in return increases the amount of insulin 
available for absorption.
14
The use of enzyme inhibitors 
in long term therapy however is considered to be highly 
risk because of possible absorption of unwanted 
proteins, disturbance of digestion of nutritive proteins & 
stimulation of protease secration.
41
The earliest studies 
regarding enzyme inhibitors were carried out with 
sodium cholate along with aprotinin which improved 
insulin absorption in rats.
5,36
 Significant hypoglycemic 
effects were also obtained following large intestinal 
administration of insulin with camostat mesilate, 
bacitracin.
5,37
 Other inhibitors which have shown 
promise effects are leupeptin
38
 , FK-448
39
, a potent & 
specific inhibitor of chymotrypsin & chicken & duck 
ovomucoid.
14
 In one study, polymers cross linked with 
azoaromatic groups formed an impervious film to 
protect insulin from digestion in the stomach & small 
intestine.
5,40
 
Modification of chemical structure:
5
 
Effective modification in the chemical structure of 
proteins and peptides may result in the appreciable 
enhancement in bioavailability by increasing its 
stability against possible enzymaytic degradation or its 
membrane penetration. Since proteins are structurally  
have more complex chemical structure as compared to 
peptides hence this approach is more applicable to 
peptides as compared to proteins. For example, 
substitution of D-amino acids for L-amino acids in the 
primary structure can improve the enzymatic stability of 
peptides
5
. A diacyl derivative of insulin maintains its 
biological activity and also increases its absorption from 
the intestine.
5
 
VARIOUS CARRIER SYSTEMS: 
Liposomes:
5
 
Dose-dependent hypoglycemia is observed in case of 
insulin-entrapped liposomes.
5
  Liposomes with varying 
composition have been prepeared by researchers via 
two methods: solvent evaporation hydration and solvent 
spherule evaporation.
5,42
 Liposomes which contain 
lecithin 100mg, cholesterol 20mg, insulin 150 units, and 
Tween 1% v/v were found to be most effective for this 
purpose.
5
 The effect of insulin-liposome was prolonged 
in diabetes-induced rabbits than that of normal rabbits.
5
 
The pharmacodynamics results of the insulin-liposome 
system was comparable with the action of 1 U/kg of 
insulin administered subcutaneously.
5 
Hydrogels:
5
 
These are cross-linked networks of hydrophilic 
polymers, which are able to absorb large amounts of 
water and swell, while maintaining their three-
dimensional structure.
5,43
 Complexation hydrogels are 
suitable candidates for oral delivery of proteins and 
peptides due to their abilities to respond to changes in 
pH in the GI tract and provide protection to the drugs 
from the harsh environment of the GI tract.
5,18
 
Nanospheres:
5
 
Iinsulin-loaded nanospheres was prepared by 
polymerization of isobutyl cyanoacrylates (IBCA) in an 
acidic medium by Damge et al.
5,44
 These nanosphere 
showed a mean size of 145nm and an association rate of 
1 U of insulin per milligram of polymer.
5
 These 
nanospheres were displayed in an oily medium (Miglyol 
812) containing surfactants (Polox-amer 188 and 
deoxycholic acid)band evaluated for in vitro and in vivo 
degradation.
5
 No in vitro  degradation was observed due 
to proteolytic enzyme.
5
 When these nanosphere (100 U 
per kilogram of body weight) were administered 
perorlly  in streptozotocin induced diabetic rats , a 50% 
decreases in fasted glucose levels from the second hours 
up to 10-13 days was observed
5
. This effect last for very 
less time period (2days) or absent when nanospheres 
were dispersed in water
5
. Using C
14
-labelled 
nanospheres loaded with (I
125
) insulin or its metabolites 
in the gastrointestinal tract, blood, and liver while the 
excretion was delayed when compared to (I
125
) insulin 
nanoassociated to nanospheres.
5
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Figure 3: Formulation of chitosan coated nanoliposomes
9 
 
 
 
Figure 4: Silica alginate nanocomposite for insulin delivery
9
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Figure 5: Thiolated polymer for oral insulin delivery
9
 
Erythrocytes:
5 
Human red blood cells have been developed as oral 
carrier systems for human insulin
5
. In a study by Al-
Achi et al., male Wistar rats were made diabetic by a 
single intraperitoneal injection of streptozocin 
(100mg/kg).
5,45
 Rats received orally one of the 
following (100 U, 2ML): an insulin solution, a ghosts-
insulin suspension, a vesicles-insulin suspension, a 
liposomes-ghosts-insulin suspension, or a liposomes-
vesicles-insulin suspension.
5
 Free-carrier suspensions or 
sodium chloride solution (0.9%)  were  given  orally   as  
controls.
5
 
Blood glucose concentration was noted before 
administration and at 1, 2. 3, 4, 5, 6, and 7 h post 
administration
5
. Results showed that all treatment 
groups, except liposomes-ghosts-insulin, were 
significantly different statistically from their respective 
controls (i.e., the free carriers).
5
 
Nanocubices:
5
 
Chung et al developed a liquid formulae that can be 
easily dispersed in water to produce particles named 
“Nanocubicles”.46 These nanocubicles containing 
insulin were administered to fasted streptozotocin 
induced diabetic rats.
5
 For comparison, an aqueous 
solution of insulin in water was also administered. 
Nanocubicles without insulin and insulin in phosphate 
buffer saline (PBS) were administered as controls. 
Blood glucose concentration and insulin concentration 
were measured 1,2,3,4, and 6 hours after administration 
of insulin formulation.
5
 In vitro experimention showed 
that the particles were absorbed by Caco-2 cells at a 
high ratio.
5
 It was observed in these studies that the 
serum glucose concentration was controlled for more 
than 6 hours after oral insulin administration but 
returned to the basal concentration in 3 hours when 1 
IU/kg of insulin was injected through intravenous 
route.
5
 
Microspheres:
10
 Insulin-loaded microspheres are 
composed of chitosan 3% (w/v), and loading 120 IU 
insulin were produced by emulsion cross-linking 
method.
10
 Cross-linking time for it is almost 5 h and 
glutaraldehyde 3.5% (v/v) is used as cross-linker.
10
To 
predict release of insulin from chitosan microspheres 
swelling ratio studies were evaluated. Bacitracin and 
sodium taurocholate are incorporated in the 
formulations as proteolytic enzyme inhibitor and 
absorption enhancer, respectively.
10
 In vitro insulin 
release studies are performed in phosphate buffer pH 
7.4 and also in HCl pH 2 with and without trypsin.
10
 In 
vitro release showed a controlled profile up to 12 h and 
the formulation containing 0.15% (w/v) of bacitracin 
revealed a maximum biological activity of about 49.1 _ 
4.1%
7
. Mathematical modeling using Higuchi and 
Korsmeyer-Peppas suggested a non-Fickian diffusion as 
the mechanism of insulin release. Insulin-loaded 
chitosan microspheres for oral delivery showed to be an 
innovative and reliable delivery system to overcome 
conventional insulin therapy.
10
 
Microspheres of chitosan are extensively used for 
providing a controlled release of peptides and proteins, 
such as insulin.
47
It helps in enhancing the 
bioavailability of  peptide , as well asthe uptake of other 
hydrophilic substances through epithelial layers with 
improved protection against the unfavorable and 
degragating environment ofstomach upon oral 
administration.
47,48
 Chitosan is a polymer with 
mucoadhesive properties that increases the contact with 
mucosa, where drugs are absorbed, resulting in a 
concentration gradient required for its absorption.
49,50
 In 
vitro profiles of drugs are important or the development 
of new drug delivery systems as an assessment of 
bioequivalence.
10
The drug release profile is linked to 
the system’s properties and determines the amount of 
drug available for absorption.
51
 Aspects related to drug 
absorption, biodistribution, metabolism and elimination 
(the so-called ADME processes) are therefore of 
upmost relevance to predict the efficiency of delivery 
systems by in vitro studies. The type of drug and 
matrix, its polymorphic form, crystallinity, particle size, 
and solubility can influence the release profile.
52
Models 
of drug release are often applied to predict controlled 
release in delivery systems such as chitosan 
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microspheres; however, it does not provide any 
information on the mechanisms that control the process. 
The use of empirical models for simulating drug release 
profiles is a function of time related to the amount of 
drug released from the pharmaceutical dosage form.
53
 
The quantitative values are interpreted bygeneric 
equations that mathematically translate the release 
curve. To understand dissolution profiles, mathematical 
models and statistical analysis are used for formulation 
and evaluation.
54
 To describe the insulin releasing 
mechanism from chitosan microspheres, release profiles 
were analyzed applying 4 different mathematical 
models, i.e. zero order, first order, Higuchi and 
Korsmeyer-Peppas. In the zero order kinetics, drug 
dissolution profiles is slow as pharmaceutical systems 
do not disaggregate, assuming no changes in dissolution 
area which is maintained under equilibrium. The 
equation translating this kinetic model is:
10
 
Q1=Q0+K0t 
where Q1 is the amount of drug dissolved in time t, Q0 
is the initial amount of drug in the solution (generally, 
Q0=0) and K0 is the zeroorder release constant. The 
graphic of drug dissolved versus timewill be linear.
10
 
In first order kinetics, the dissolution phenomenon of a 
solid particle in a liquid media implies a surface action 
and from severaldeductions. The equation in decimal 
logarithms can be depicted as:
10
 
logQt = logQ0 + K1t/2.303 
where Qtis the amount of drug released at time t, Q0 is 
the amount of drug in the solution, and K1 is the first 
order release constant. The graphic of the decimal 
logarithm of the released amount of drug versus time 
will be linear. This model is usually applied for 
dissolution profiles of water-soluble drugs in porous 
matrices.
10
 
Higuchi model is based on the quantification of drug 
release derived by applying in this equation. This model 
describes a direct proportionality between the 
cumulative amount of drug released overtime based on 
a pseudo-steady-state approach.
55,56
 For Higuchi model, 
the drug release can be defined as the mass transfer of 
drug molecules from the dosage form to the 
surrounding medium in which drug release takes place. 
Higuchi equation allows device optimization, 
underlying drug release mechanisms. 
56
 Higuchi model 
describes the release of drugs as the square root of time 
based on the Fickian diffusion and hence forth the 
simplified equation is:
10
 
ft = KH * t
1/2 
 
where KH is the constant reflecting the design variables 
of thesystem.
57
 
Korsmeyer-Peppas model is based on the Fick’s Law. 
This modelis used to describe the release of the solute 
when the prevailing mechanism is a combination of 
drug diffusion -Fickian transport-,and in Case II 
transport -non-Fickian-, controlled by the relaxation of 
polymer chains.
57,58
 Korsmeyer-Peppas model is useful 
to predict the release mechanism in the first 10 h being 
described bythe following equation:
10
 
Mt/M∞  = K * t
n
 
 Where Mt/M∞  is the fraction of drug released at time t, 
K is the rate constant, and n is the diffusion exponent. 
According to this model, the value of n identifies the 
release mechanism of drug. Values of n between 0.5 
and 1.0 indicate anomalous transport kinetics, n 
approximately 0.5 indicates the pure diffusion 
controlled mechanism (Fickian diffusion). The smaller 
n values below 0.5 may be dueto drug diffusion 
partially through a swollen matrix and water filled pores 
in the formulations.
59,60
 This model is often applied for 
the analysis of the release profile of drugs in polymeric 
systems.
10
 
FURTHER APPROACHES:
5
 
Tablets:
5
 
Thiolated chitosan insulin tablets:
5 
The another 
approach for improving  efficacy of orally administered 
insulin is by using thiolated chitosan. 2-Iminothiolane 
was covalently linked to chitosan and the resulting 
chitosan-TBA (chitosan-4-thiobutylamidine) conjugate 
exhibited 453.5=64.1micromole thiol group per gram of 
polymer
61
. Bowman-Birk-Inhibitor (BBI) and 
Elastatinal two enzyme inhibitors,were covalently 
linked to chitosan. Chitosan-TBA conjugate (5 mg), 
insulin (2.75 mg), the permeation mediator reducer 
glutathione (0.75mg), and the two inhibitor conjugates 
(in each case 0.75 mg) were compressed to make 
chitosan-TBA-insulin tablets. Control tablets were also 
prepared using chitosan and insulin. Chitosan-TBA-
insulin tablets produced a controlled release of insulin 
over 8 h. In vitro mucoadhesion studies suggests that 
the mucoadhesive / cohesive properties of chitosan were 
at least 60-fold improved by the immobilization of thiol 
groups on the polymer. 
Microemulsions:
5 
Cho and Flynn developed water-in-oil microemulsions 
in which the aqueous phase is insulin and oil phase is 
lecithin, non-esterifies fatty acids and cholesterol in 
critical proportions
28
. In vivo studies demonstrated that 
microemulsions substantial reduction in blood glucose 
level. Recent research has focused on enteric-coated dry 
emulsion formulations prepared from solid-in-oil-in-
water emulsions. These mode of administration 
responded to changes in external environment 
suggesting potential application for oral insulin 
delivery.
25
 
Oral Insulin pills:
5
 
This mode of insulin administration has so many 
limitations associated with it and efficacy regarding it 
has been hard to demonstrate. Main focus of research 
regarding this mode of administration is to overcome 
these limitations by stabilizing the degradation, 
improving the permeability, and adding absorption 
promoters to protect the insulin as it passes through the 
stomach.
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Figure 6: Chitosan as an effective polymer for oral administration of insulin
9 
 
Oral Spray:
5
 
Oral mouth spray containing insulin when administered 
would be absorbed through the lining of the mouth and 
throat. The liquid formulation allows the insulin to be 
absorbed by the mucus membranes in the cheeks, 
tongue, and throat. The benefit from oral spray is 
identical to an insulin injection in its ability to lower 
blood glucose levels. 
Pulmonary or inhaled insulin:
5
 
In case of inhalational delivery system of insulin, a dose 
of insulin, either in liquid or dry powder form, delivered 
through the mouth, directly into the lungs, where it 
enters the blood circulation as rapid-acting insulin. The 
highly permeable alveolar epithelium and large surface 
area of the lungs provide an effective, efficient portal 
for macromolecular delivery i.e. inhaled insulin. 
MARKET STATUS OF ORAL INSULIN 
PRODUCTS:
5
 
IN-105 (Biocon, Bangalore)
5 
Biocon is developing the IN-105 conjugated insulin 
molecule, administered as a tablet.
5
 This oral insulin pill 
has polymers added at specific locations in the B chain 
of the insulin to prevent insulin from getting degraded 
in the stomach by degragating environment (insulin is 
made up of two polypeptide chains namely, chain- with 
21 amino acids and chain-B with 30 amino acids, which 
are held together by two disulfide bonds).
5
 Biocon’s 
R&D group has successfully developed a carefully 
selected formulation to give consistent absorption 
through the intestines, delivering the glucose-lowering 
effect.
5
 In the clinic, this molecule has completed phase 
1 trials and is expected to enter phase 2 in India later 
this year to illustrate proof of concept.
5
 The 
encouraging results of the phase 1a and 1b studies 
represent a pivotal hurdle crossed in the development 
on IN-105 as a product.
5 
Oral-Lyn (Generex Biotechnology, Canada)
5
 
Oral-Lyn is the proprietary oral insulin spray product of 
company Genex Biotechnology, Canada. Oral-Lyn  
contains a liquid formulation which is  absorbed into the 
body by the lining of the inner mouth using the 
company’s proprietary RapidMist device.5 As  it is 
buccally absorbed, no insulin is deposited in the lungs 
by the Oral-Lyn RapidMist.
5
  The commercial launch of 
Oral-Lynwas launched in Indian market on August 
2007.
5
 Generex Biotechnology entered into Master 
Product Licensing and Distribution Agreement of Oral-
Lyn with Shreya Life Sciences, whichis the fourth 
largest distributor of insulin product  in India.
5
Generex 
entered into a similar agreement for the distribution of 
Oral-lyn in China, Hong Kong, and the following 
additional countries: Indonesia, South Korea, Malaysia, 
the Philippines in april 2008. Generex Oral-Lyn is in 
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phase 3 clinical trials at several sites around the world-
US, Canada and Ukraine.
5 
Transgene (Biotek, Andhra Pradesh)
5 
Transgene has developed an oral delivery technology 
which combines several oral delivery approaches into a 
single drug delivery system.
5
 Applying veryunique 
approach, this technology involves using biodegradable 
novel polymeric nanoparticles loaded with insulin as a 
new carrier to transport the insulin across the intestinal 
epithelial tissues.
5
 Nanoparticles are solid spherical 
particles with a size range of 10 and 1,000nm 
containing dispersed drugs.
5
 Transgene has attempted to 
improve the intestinal absorption of insulin and other 
peptides.
5
 The technology has been well proven in 
animal models, and human clinical studies are in 
progress.
5
 Drug companies are quit interested in the 
potential of oral insulin delivery to net a massive share 
of the market, and therefore, investment in research is 
substantial and still ongoing.
5
 
Transgene Biotek , Biocon,and Generex Biotechnology 
have proven that they are insightful in the race of oral 
insulin delivery and definitely doing a revolutionary 
work in history of insulin replacement therapy.
5 
CONCLUSION: 
The present route of insulin administration is by 
subcutaneous route by which insulin is presented to the 
body of patient in a non – physiological manner. Insulin 
if administered via oral route will help to eliminate the 
pain caused by injection, psychological barriers 
associated with multiple daily injections such as needle 
anxiety and possible infections . In addition, oral insulin 
is advantageous because it is delivered directly on the 
liver, its primary site of action , via the portal 
circulation , a mechanism very similar to endogenous 
insulin subcutaneous insulin treatment . The oral route 
is considered to be most acceptable and convenient 
route of administration for chronic therapy. Attempts 
have been made to achieve oral insulin delivery using 
various systems. It has been proven that insulin is 
subjected to acid catalyzed degradation in stomach, 
luminal degradation in intestine, and intracellular 
degradation. Scientists have been able to protect the 
insulin delivery systems from acidic environment of the 
stomach and target it to the intestine. Liposomes, 
microemulsions, nanocubicles, thiolated chitosan, 
chitosan microspheres and so forth have been prepared 
for the oral delivery of insulin. Further attempts have 
been made to increase the absorption enhancers such as 
a protinin (protease inhibitor), tween, oligoarginine, 
sodium glycol-cholate, deoxycholic acid, and 
taurodeoxycholate and membrane permeation enhancer 
examtheple surfactants. Overcoming limitation of these 
absorption enhancers and  facilitators for membrane 
permeation is the main focus of recent research for 
development of satisfactory oral insulin delivery 
formulation.  
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